A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study

Killer immunoglobulin-like receptor (KIR) genes participate in the regulation of natural killer (NK) cell function, and mismatch between transplant donor and recipient improves clinical outcomes in some transplantation settings [1-6]. Lower than expected rates of relapse, graft failure, and graft-versus-host disease (GVHD) occur in KIR-incompatible, T cell-depleted, HLA-mismatched related donor hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) [5]. Similarly, Hsu et al [7] reported superior overall survival (OS) and disease-free survival (DFS) for recipients of KIR-incompatible HCST compared with recipients of KIR-compatible HSCT for AML and myelodysplastic syndrome with HLA-identical sibling donors.

Source: Biology of Blood and Marrow Transplantation - December 19, 2019 Category: Hematology Authors: Stella M. Davies, Robert Iannone, Todd A. Alonzo, Yi-Cheng Wang, Robert Gerbing, Sandeep Soni, E. Anders Kolb, Soheil Meshinchi, Paul J. Orchard, Linda J. Burns, Shalini Shenoy, Wing Leung Source Type: research